UK MHRA Draws Up A Roadmap Of Patient Protection And Rapid Science Uptake
The UK's health care products regulator wants to capitalize on its post-EU, standalone status by setting an agenda for change that protects public health through excellence in regulation and science.
You may also be interested in...
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
The UK devices regulator will prioritize innovation, global best practice and enhanced patient safety and the patient voice, MHRA board chairman Stephen Lightfoot said during the ABHI’s spring regulatory conference. New fees for industry are also on the cards.
China ambitiously wants to champion domestic medtech manufacturers in the global market. It also needs to ensure foreign manufacturers do not sustainably dominate its home market – while also benefiting from their technical expertise, for the time being at least. Against that backdrop, new Chinese data laws are being eyed by global medtechs with a certain trepidation.